Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
for Breast Cancer
8 locations incl. Columbia
Sponsor: SCRI Development Innovations, LLC
Sex: All·Age: 18+
Code: NCT05748834·Phase 2·Recruiting